HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer.

AbstractOBJECTIVE:
To determine whether serum Zic4 antibodies associate with paraneoplastic neurologic disorders (PND) and small-cell lung cancer (SCLC), and the association of these antibodies with other onconeuronal immunities associated with SCLC.
DESIGN/METHODS:
The authors studied 498 patients (215 with PND and 283 without PND or without cancer). The presence of antibodies was tested with immunoblots of Zic4, HuD, and CRMP5 proteins. The tumor expression of these proteins was determined by immunohistochemistry.
RESULTS:
Zic4 antibodies were identified in 61 patients. Ninety-two percent of patients with Zic4 antibodies had SCLC; detection of these antibodies segregated with the presence of PND (p = 0.031). Intrathecal synthesis of Zic4 antibodies was demonstrated in 5/7 patients with PND. None of 175 control patients without PND or cancer had Zic4 antibodies. Because of the robust association between Zic autoimmunity and SCLC, all patients were tested for other SCLC-related antibodies; concurrent Zic4, Hu, or CRMP5 antibodies occurred in the serum or CSF of 27% of SCLC patients with PND. Patients with isolated Zic4 antibodies were more likely to develop predominant cerebellar dysfunction than patients with several immunities (p < 0.001). Tumors of patients with and without onconeuronal antibodies coexpressed Zic, Hu, and CRMP5 proteins, indicating that the tumor expression of these antigens is necessary, but not sufficient, for immunologic activation.
CONCLUSIONS:
In patients with neurologic symptoms of unknown cause detection of Zic4 antibodies predicts a neoplasm, usually a SCLC, and suggests that the neurologic disorder is paraneoplastic. Detection of Zic4 antibodies often associates with anti-Hu or CRMP5 antibodies. Patients with isolated Zic4 antibodies are more likely to develop cerebellar dysfunction than those with concurrent immunities.
AuthorsL Bataller, D F Wade, F Graus, H D Stacey, M R Rosenfeld, J Dalmau
JournalNeurology (Neurology) Vol. 62 Issue 5 Pg. 778-82 (Mar 09 2004) ISSN: 1526-632X [Electronic] United States
PMID15007130 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antibodies, Neoplasm
  • ELAV Proteins
  • ELAV-Like Protein 4
  • ELAVL4 protein, human
  • Microtubule-Associated Proteins
  • Nerve Tissue Proteins
  • RNA-Binding Proteins
  • Transcription Factors
  • ZIC4 protein, human
  • DPYSL5 protein, human
  • Hydrolases
Topics
  • Aged
  • Aged, 80 and over
  • Antibodies, Neoplasm (blood, cerebrospinal fluid, metabolism)
  • Carcinoma, Small Cell (immunology, metabolism)
  • ELAV Proteins
  • ELAV-Like Protein 4
  • Female
  • Humans
  • Hydrolases
  • Immunoblotting
  • Immunohistochemistry
  • Lung Neoplasms (immunology, metabolism)
  • Male
  • Microtubule-Associated Proteins
  • Middle Aged
  • Nerve Tissue Proteins (immunology, metabolism)
  • Paraneoplastic Polyneuropathy (diagnosis, immunology, metabolism)
  • RNA-Binding Proteins (immunology, metabolism)
  • Transcription Factors (immunology, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: